Table 4.
Diagnostic performance of preliminary models to predict malignant IPMN pathology1.
| Model/Variables included | AUC (95% CI) | p value | FDR | Accuracy | SE | SP | PPV | NPV |
|---|---|---|---|---|---|---|---|---|
| Gender | 0.60 (0.43 ~ 0.78) | 0.242 | 0.252 | 0.61 | 0.50 | 0.71 | 0.58 | 0.63 |
| Jaundice | 0.61 (0.48 ~ 0.75) | 0.087 | 0.095 | 0.65 | 0.29 | 0.94 | 0.80 | 0.62 |
| High risk stigmata (HRS) | 0.84 (0.71 ~ 0.97) | 0.0002 | 0.004 | 0.84 | 0.86 | 0.82 | 0.80 | 0.88 |
| Worrisome features (WF) | 0.53 (0.36 ~ 0.70) | 0.690 | 0.690 | 0.52 | 0.71 | 0.35 | 0.48 | 0.60 |
| lncRNA signature | 0.76 (0.58 ~ 0.94) | 0.012 | 0.022 | 0.77 | 0.79 | 0.76 | 0.73 | 0.81 |
| miRNA signature | 0.79 (0.63 ~ 0.96) | 0.035 | 0.043 | 0.74 | 0.86 | 0.65 | 0.67 | 0.85 |
| Radiomics signature | 0.74 (0.55 ~ 0.93) | 0.014 | 0.023 | 0.77 | 0.86 | 0.71 | 0.71 | 0.86 |
| miRNAs + Radiomics | 0.89 (0.76 ~ 1.00) | 0.002 | 0.009 | 0.87 | 0.79 | 0.94 | 0.92 | 0.84 |
| lncRNAs + Radiomics | 0.78 (0.61 ~ 0.95) | 0.010 | 0.021 | 0.81 | 1.00 | 0.65 | 0.70 | 1.00 |
| lncRNAs + miRNAs | 0.83 (0.67 ~ 0.99) | 0.013 | 0.023 | 0.81 | 0.79 | 0.82 | 0.79 | 0.82 |
| lncRNAs + Radiomics + miRNAs | 0.90 (0.78 ~ 1.00) | 0.004 | 0.010 | 0.87 | 0.71 | 1.00 | 1.00 | 0.81 |
| HRS + WF + lncRNAs | 0.91 (0.81 ~ 1.00) | 0.001 | 0.007 | 0.87 | 0.86 | 0.88 | 0.86 | 0.88 |
| HRS + WF + Radiomics | 0.85 (0.70 ~ 1.00) | 0.002 | 0.009 | 0.84 | 0.86 | 0.82 | 0.80 | 0.88 |
| HRS + WF + miRNAs | 0.94 (0.87 ~ 1.00) | 0.001 | 0.007 | 0.87 | 0.93 | 0.82 | 0.81 | 0.93 |
| HRS + WF + lncRNAs + Radiomics | 0.91 (0.81 ~ 1.00) | 0.003 | 0.009 | 0.87 | 0.86 | 0.88 | 0.86 | 0.88 |
| HRS + WF + lncRNAs + miRNAs | 0.95 (0.89 ~ 1.00) | 0.001 | 0.007 | 0.87 | 0.93 | 0.82 | 0.81 | 0.93 |
| HRS + WF + lncRNAs + Radiomics + miRNAs | 0.95 (0.89 ~ 1.00) | 0.003 | 0.009 | 0.87 | 0.93 | 0.82 | 0.81 | 0.93 |
| HRS + WF + gender + Jaundice + lncRNAs + Radiomics + miRNAs | 0.97 (0.91 ~ 1.00) | 0.010 | 0.021 | 0.90 | 0.93 | 0.88 | 0.87 | 0.94 |
| WF + lncRNAs | 0.76 (0.59 ~ 0.94) | 0.041 | 0.049 | 0.77 | 0.71 | 0.82 | 0.77 | 0.78 |
| WF + Radiomics | 0.78 (0.60 ~ 0.95) | 0.021 | 0.031 | 0.81 | 1.00 | 0.65 | 0.70 | 1.00 |
| WF + miRNAs | 0.79 (0.62 ~ 0.96) | 0.067 | 0.076 | 0.81 | 0.79 | 0.82 | 0.79 | 0.82 |
| WF + lncRNAs + Radiomics | 0.82 (0.66 ~ 0.97) | 0.015 | 0.024 | 0.77 | 0.86 | 0.71 | 0.71 | 0.86 |
| WF + lncRNAs + miRNAs | 0.84 (0.69 ~ 1.00) | 0.029 | 0.039 | 0.84 | 0.86 | 0.82 | 0.80 | 0.88 |
| WF + lncRNAs + Radiomics + miRNAs | 0.92 (0.83 ~ 1.00) | 0.007 | 0.018 | 0.87 | 0.93 | 0.82 | 0.81 | 0.93 |
| WF + gender + Jaundice + lncRNAs + Radiomics + miRNAs | 0.92 (0.82 ~ 1.00) | 0.027 | 0.037 | 0.87 | 0.93 | 0.82 | 0.81 | 0.93 |
131 IPMN cases (17 benign; 14 malignant) had data types (clinical data, miRNA, radiomic, lncRNA) included in these analyses. AUC = area underneath the curve; SE = sensitivity; SP = specificity; PPV = positive predictive value; NPV = negative predictive value; High risk stigmata = main pancreatic duct involvement/dilatation ≥10 mm, obstructive jaundice with a cystic lesion in the pancreatic head, or an enhanced solid component/nodule within the cyst; Worrisome features = main pancreatic duct dilation 5–9 mm, cyst size >3 cm, thickened enhanced cyst walls, non-enhanced mural nodules, or acute pancreatitis.